Skip to content

Stock-Based Comp at other companies

Revvity logo
RevvityRVTY
Charles River Laboratories logo
Charles River LaboratoriesCRL
CareDx logo
CareDxCDNA
Haemonetics logo
HaemoneticsHAE
Zoetis logo
ZoetisZTS
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO

Other financials

Income statement

See full
Revenue$619.8M-10.5%
Gross profit$263.8M-23.2%
Operating income-$31.8M-198%
Net income-$91.8M-623%
EPS (diluted)-$1.35-611%

Balance sheet

See full
Cash & equivalents$140.4M+10.4%
Total debt$3.1B+0.3%
Total equity$1.9B-38.2%
Total assets$5.6B-12.9%

Cash flow

See full
Operating cash flow-$33.0M-150%
CapEx$34.0M-39.5%
Free cash flow-$67.0M-813%

Valuation

See full
Market cap$921.94M-51.4%
Enterprise value$3.88B-20.1%
P/S0.4×-0.3×

Profitability

See full
Gross margin45%-2.0pp
Operating margin-37%-46.2pp
Net margin-45.6%-75.7pp
FCF margin13.8%

Returns & leverage

See full
Return on equity-49.9%-70.8pp
Debt / equity1.7×+0.6×
Current ratio1.4×+0.2×

Where this comes from

Reported directly by QuidelOrtho Corporation in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: QuidelOrtho Corporation’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about QuidelOrtho Corporation's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is QuidelOrtho Corporation's stock-based comp?
QuidelOrtho Corporation (QDEL) reported stock-based comp of $10.7M in Q1 2026.
How has QuidelOrtho Corporation's stock-based comp changed year-over-year?
QuidelOrtho Corporation's stock-based comp decreased by 7.8% year-over-year, from $11.6M to $10.7M.
What is the long-term trend for QuidelOrtho Corporation's stock-based comp?
Over 3 years (2022 to 2025), QuidelOrtho Corporation's stock-based comp has grown at a -1.8% compound annual growth rate (CAGR), from $48.4M to $45.9M.